13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001534261
Total reported value
$2.0B
$2.0B
38 檔
45.7%
In Q4 2024, Casdin Capital, LLC's U.S. equity holdings reached a combined market value of $2.0B, distributed across 38 disclosed stock positions.
In Q4 2024, Casdin Capital, LLC displayed an active expansion posture, initiating 5 new positions and adding to 3 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including WGS, BLFS, RVMD) accounted for 45.7% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | WGS | Genedx Holdings CORP | Stock-Other | 17.94% | -1.88% | — | |
| 2 | BLFS | Biolife Solutions Inc | Stock-Other | 15.04% | -2.03% | — | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 10.77% | +5.18% | -10.09% | |
| 4 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 8.69% | +0.42% | NEW | |
| 5 | LAB | Standard Biotools Inc | Stock-Other | 8.30% | -2.52% | — | |
| 6 | ILMN | Illumina Inc | Stock-Healthcare | 6.67% | -0.29% | — | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.96% | — | -1.91% | |
| 8 | CDXS | Codexis Inc | Stock-Other | 2.57% | — | — | |
| 9 | RLAY | Relay Therapeutics Inc | Stock-Other | 2.45% | +4.16% | -3.27% | |
| 10 | EXK | Exact Sciences CORP | Stock-Materials | 2.43% | — | — | |
| 11 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.19% | -0.75% | -17.65% | |
| 12 | BEAM | Beam Therapeutics Inc | Stock-Other | 2.06% | -0.12% | +61.29% | |
| 13 | NGNE | Neurogene Inc | Stock-Other | 1.97% | +0.26% | +146.92% | |
| 14 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.89% | — | — | |
| 15 | NTLA | Intellia Therapeutics Inc | Stock-Other | 1.55% | -0.04% | — | |
| 16 | ✓ | Verve Therapeutics Inc | Stock-Other | 1.50% | — | — | |
| 17 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.34% | -0.05% | — | |
| 18 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.26% | -1.13% | — | |
| 19 | MRNA | Moderna Inc | Stock-Healthcare | 0.97% | -0.03% | — | |
| 20 | SEPN | Septerna Inc | Stock-Other | 0.84% | -0.08% | — | |
| 21 | VCYT | Veracyte Inc | Stock-Other | 0.73% | +0.14% | -58.53% | |
| 22 | GH | Guardant Health Inc | Stock-Healthcare | 0.71% | -0.81% | — | |
| 23 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.64% | -0.01% | — | |
| 24 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.55% | — | — | |
| 25 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.43% | — | — | |
| 26 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.42% | — | — | |
| 27 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.39% | — | — | |
| 28 | IPSC | Century Therapeutics Inc | Stock-Other | 0.35% | -0.06% | +61.58% | |
| 29 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 0.34% | — | — | |
| 30 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.29% | -0.03% | — | |
| 31 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.24% | — | — | |
| 32 | ABSI | Absci CORP | Stock-Other | 0.17% | +0.34% | — | |
| 33 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.13% | -0.01% | — | |
| 34 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.07% | -0.01% | — | |
| 35 | PRME | Prime Medicine Inc | Stock-Other | 0.07% | -0.25% | — | |
| 36 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.04% | — | — | |
| 37 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.02% | — | — | |
| 38 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | WGS | Genedx Holdings CORP | +8% | — | Unchanged |
| 2 | MRNA | Moderna Inc | +1% | NEW | New buy |
| 3 | CDXS | Codexis Inc | +0.9% | — | Unchanged |
| 4 | SEPN | Septerna Inc | +0.8% | NEW | New buy |
| 5 | BEAM | Beam Therapeutics Inc | +0.8% | +61.29% | Add |
| 6 | AGIO | Agios Pharmaceuticals Inc | +0.6% | NEW | New buy |
| 7 | BLFS | Biolife Solutions Inc | +0.5% | — | Unchanged |
| 8 | NGNE | Neurogene Inc | +0.5% | +146.92% | Add |
| 9 | FTRE | Fortrea Holdings Inc | +0.3% | NEW | New buy |
| 10 | ✓ | Verve Therapeutics Inc | +0.2% | — | Unchanged |
| 11 | GH | Guardant Health Inc | +0.2% | — | Unchanged |
| 12 | ILMN | Illumina Inc | +0.2% | — | Unchanged |
| 13 | RXRX | Recursion Pharmaceuticals-a | +0.1% | NEW | New buy |
| 14 | GLUE | Monte Rosa Therapeutics Inc | 0% | — | Unchanged |
| 15 | PACB | Pacific Biosciences Of Calif | 0% | — | Unchanged |
| 16 | DNA | Ginkgo Bioworks Holdings Inc | — | — | Unchanged |
| 17 | KRON1USD | Kronos Bio Inc | — | — | Unchanged |
| 18 | PRME | Prime Medicine Inc | 0% | — | Unchanged |
| 19 | IPSC | Century Therapeutics Inc | 0% | +61.58% | Add |
| 20 | EXAIEUR | Exscientia PLC | -0.1% | EXIT | Sold out |
| 21 | ABSI | Absci CORP | -0.1% | — | Unchanged |
| 22 | CTNM | Contineum Therapeutics Inc-a | -0.1% | — | Unchanged |
| 23 | 2655787D | Blueprint Medicines CORP | -0.1% | — | Unchanged |
| 24 | SNDX | Syndax Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 25 | TNYA | Tenaya Therapeutics Inc | -0.2% | — | Unchanged |
| 26 | TSVT* | 2seventy Bio Inc | -0.2% | — | Unchanged |
| 27 | SRPT | Sarepta Therapeutics Inc | -0.3% | — | Unchanged |
| 28 | GRAL | Grail Inc | -0.3% | EXIT | Sold out |
| 29 | TNGX | Tango Therapeutics Inc | -0.4% | — | Unchanged |
| 30 | FDMT | 4d Molecular Therapeutics In | -0.4% | — | Unchanged |
| 31 | EXK | Exact Sciences CORP | -0.5% | — | Unchanged |
| 32 | DNLI | Denali Therapeutics Inc | -0.6% | — | Unchanged |
| 33 | VCYT | Veracyte Inc | -0.8% | -58.53% | Trim |
| 34 | GPCR | Structure Therapeutics Inc | -0.8% | — | Unchanged |
| 35 | LAB | Standard Biotools Inc | -0.9% | — | Unchanged |
| 36 | ALNY | Alnylam Pharmaceuticals Inc | -0.9% | -17.65% | Trim |
| 37 | NTLA | Intellia Therapeutics Inc | -1.2% | — | Unchanged |
| 38 | RVMD | Revolution Medicines Inc | -1.7% | -10.09% | Trim |
| 39 | RLAY | Relay Therapeutics Inc | -1.9% | -3.27% | Trim |
| 40 | RNAGBP | Avidity Biosciences Inc | -2.4% | -1.91% | Trim |
According to official SEC Form 13F filings, Casdin Capital, LLC reported a total U.S. public equity portfolio value of $2.0B across 38 disclosed positions in Q4 2024.
During Q4 2024, Casdin Capital, LLC's top holdings by market value included WGS (17.9%)、BLFS (15.0%)、RVMD (10.8%). The largest single position, WGS, represented 17.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
MRNA
市值: $14.6M
Top Position Liquidated / Trimmed
GRAL
前期市值: $4.8M
In Q4 2024, Casdin Capital, LLC made 15 total portfolio adjustments, initiating 5 new buys, adding to 3 positions, trimming 5 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.